Results 61 to 70 of about 13,334 (226)

Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma

Respiratory Research, 2017
Background Small non-coding RNAs (microRNAs) have been evolved to master numerous cellular processes. Genetic variants within microRNA seed region might influence microRNA biogenesis and function.
Eman A. Toraih, Mohammad H. Hussein, Essam Al Ageeli, Eman Riad, Nouran B. AbdAllah, Ghada M. Helal, Manal S. Fawzy   +6 more
doaj   +1 more source

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

Pulmonary Therapy, 2019
Introduction To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk ...
Riju Ray, Beth Hahn, Richard H. Stanford, John White, Breanna Essoi, Alyssa Goolsby Hunter   +5 more
doaj   +1 more source

[Bronchodilator agents in obstructive bronchitis in infants].

Revista chilena de pediatria, 1982
M Calvo-gil
openaire   +2 more sources

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients

International Journal of COPD, 2020
José Luis López-Campos,1,2 Bernardino Alcázar Navarrete,3 Juan Antonio Riesco Miranda,2,4 Borja G Cosío,2,5 Juan P de-Torres,6 Bartolomé Celli,7 Carlos A Jiménez-Ruiz,8 Ciro Casanova Macario9 1Unidad Mé ...
López-Campos JL, Alcázar Navarrete B, Riesco Miranda JA, Cosío BG, de-Torres JP, Celli B, Jiménez-Ruiz CA, Casanova Macario C   +7 more
doaj  

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

Pulmonary Therapy, 2019
Inhaled fixed-dose combinations (FDCs) of a long-acting β-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients.
Anthony D’Urzo, Kenneth R. Chapman, James F. Donohue, Peter Kardos, M. Reza Maleki-Yazdi, David Price   +5 more
doaj   +1 more source

Current and potential improvements in the treatment of asthma from increased understanding of airway pathophysiology

Allergology International, 2002
The mainstay of chronic asthma management consists of using pharmacological agents that induce bronchodilatation, such as short-acting β-adrenergic receptor agonists (bronchodilators or relievers), and that control the chronic inflammatory process, such ...
Kian Fan Chung
doaj   +1 more source

Tracheal relaxing effects and β₂ adrenoceptor selectivity of S1319, a novel sponge‐derived bronchodilator agent, in isolated guinea‐pig tissues [PDF]

, 1999
Hidefumi Suzuki, Akihiro Ueno, Masao Takei, Kazutoshi Sindo, Toru Miura, Masayuki Sakakibara, Tatsuo Higa, Hiromi Fukamachi   +7 more
openalex   +1 more source

Evaluating bronchodilator response in pediatric patients with post-infectious bronchiolitis obliterans: use of different criteria for identifying airway reversibility

Jornal Brasileiro de Pneumologia
Objective: Post-infectious bronchiolitis obliterans (PIBO) is a clinical entity that has been classified as constrictive, fixed obstruction of the lumen by fibrotic tissue.
Rita Mattiello, Paula Cristina Vidal, Edgar Enrique Sarria, Paulo Márcio Pitrez, Renato Tetelbom Stein, Helena Teresinha Mocelin, Gilberto Bueno Fischer, Marcus Herbert Jones, Leonardo Araújo Pinto   +8 more
doaj   +1 more source

Are there specific clinical characteristics associated with physician’s treatment choices in COPD?

Respiratory Research, 2019
Background The number of pharmacological agents and guidelines available for COPD has increased markedly but guidelines remain poorly followed. Understanding underlying clinical reasoning is challenging and could be informed by clinical characteristics ...
Nicolas Roche, Anestis Antoniadis, David Hess, Pei Zhi Li, Eric Kelkel, Sylvie Leroy, Christophe Pison, Pierre-Régis Burgel, Bernard Aguilaniu, COLIBRI COPD Research Group   +9 more
doaj   +1 more source

Equivalência farmacêutica da formulação combinada de budesonida e formoterol em cápsula única com dispositivo inalador de pó Pharmaceutical equivalence of the combination formulation of budesonide and formoterol in a single capsule with a dry powder inhaler

Jornal Brasileiro de Pneumologia, 2012
OBJETIVO: Avaliar a equivalência farmacêutica da formulação teste (associação fixa de budesonida e fumarato de formoterol em cápsula única dispensada com o dispositivo Aerocaps®) em relação a uma formulação referência (budesonida e fumarato de formoterol
Marina Andrade-Lima, Luiz Fernando Ferreira Pereira, Ana Luisa Godoy Fernandes   +2 more
doaj   +1 more source